Detalhe da pesquisa
1.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38012435
2.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Hematol Oncol
; 41(5): 877-883, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37392141
3.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319575
4.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31877211
5.
Myeloid neoplasms and autoimmune diseases: markers of association.
Clin Exp Rheumatol
; 40(1): 49-55, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33427624
6.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
7.
Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network.
Ann Hematol
; 100(5): 1139-1147, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742225
8.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33388860
9.
Myeloproliferative and lymphoproliferative disorders: State of the art.
Hematol Oncol
; 38(2): 121-128, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31833567
10.
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
Ann Hematol
; 99(1): 65-72, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31832751
11.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32474619
12.
The CoV-2 outbreak: how hematologists could help to fight Covid-19.
Pharmacol Res
; 157: 104866, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387301
13.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Eur J Haematol
; 105(3): 286-291, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365249
14.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30892724
15.
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Ann Hematol
; 98(8): 1885-1890, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044260
16.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Hematol Oncol
; 39(4): 570-574, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34258787
17.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Hematol Oncol
; 38(4): 607-610, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32602167
18.
COVID-19: the new challenge for rheumatologists. First update.
Clin Exp Rheumatol
; 38(3): 373-382, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452355
19.
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
Int J Mol Sci
; 16(9): 22811-29, 2015 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26402671
20.
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.
Pharmaceutics
; 16(3)2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38543276